Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program

Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016. Omadacycline was active against Staphylococcus aureus (MIC(50)/MIC(90), 0.12/0.25 mg/liter), including methicillin-resistant S. aureus (MRSA); streptoco...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfaller, Michael A., Huband, Michael D., Shortridge, Dee, Flamm, Robert K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Epidemiology and Surveillance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913935/
https://www.ncbi.nlm.nih.gov/pubmed/29378719
http://dx.doi.org/10.1128/AAC.02327-17
_version_ 1783316628500381696
author Pfaller, Michael A.
Huband, Michael D.
Shortridge, Dee
Flamm, Robert K.
author_facet Pfaller, Michael A.
Huband, Michael D.
Shortridge, Dee
Flamm, Robert K.
author_sort Pfaller, Michael A.
collection PubMed
description Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016. Omadacycline was active against Staphylococcus aureus (MIC(50)/MIC(90), 0.12/0.25 mg/liter), including methicillin-resistant S. aureus (MRSA); streptococci (MIC(50)/MIC(90), 0.06/0.12 mg/liter), including Streptococcus pneumoniae, viridans group streptococci, and beta-hemolytic streptococci; Enterobacteriaceae, including Escherichia coli (MIC(50)/MIC(90), 0.5/2 mg/liter); Haemophilus influenzae (MIC(50)/MIC(90), 1/1 mg/liter); and Moraxella catarrhalis (MIC(50)/MIC(90), 0.25/0.25 mg/liter). Omadacycline merits further study in serious infections where resistant pathogens may be encountered.
format Online
Article
Text
id pubmed-5913935
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-59139352018-05-07 Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program Pfaller, Michael A. Huband, Michael D. Shortridge, Dee Flamm, Robert K. Antimicrob Agents Chemother Epidemiology and Surveillance Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016. Omadacycline was active against Staphylococcus aureus (MIC(50)/MIC(90), 0.12/0.25 mg/liter), including methicillin-resistant S. aureus (MRSA); streptococci (MIC(50)/MIC(90), 0.06/0.12 mg/liter), including Streptococcus pneumoniae, viridans group streptococci, and beta-hemolytic streptococci; Enterobacteriaceae, including Escherichia coli (MIC(50)/MIC(90), 0.5/2 mg/liter); Haemophilus influenzae (MIC(50)/MIC(90), 1/1 mg/liter); and Moraxella catarrhalis (MIC(50)/MIC(90), 0.25/0.25 mg/liter). Omadacycline merits further study in serious infections where resistant pathogens may be encountered. American Society for Microbiology 2018-03-27 /pmc/articles/PMC5913935/ /pubmed/29378719 http://dx.doi.org/10.1128/AAC.02327-17 Text en Copyright © 2018 Pfaller et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Epidemiology and Surveillance
Pfaller, Michael A.
Huband, Michael D.
Shortridge, Dee
Flamm, Robert K.
Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program
title Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program
title_full Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program
title_fullStr Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program
title_full_unstemmed Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program
title_short Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program
title_sort surveillance of omadacycline activity tested against clinical isolates from the united states and europe as part of the 2016 sentry antimicrobial surveillance program
topic Epidemiology and Surveillance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913935/
https://www.ncbi.nlm.nih.gov/pubmed/29378719
http://dx.doi.org/10.1128/AAC.02327-17
work_keys_str_mv AT pfallermichaela surveillanceofomadacyclineactivitytestedagainstclinicalisolatesfromtheunitedstatesandeuropeaspartofthe2016sentryantimicrobialsurveillanceprogram
AT hubandmichaeld surveillanceofomadacyclineactivitytestedagainstclinicalisolatesfromtheunitedstatesandeuropeaspartofthe2016sentryantimicrobialsurveillanceprogram
AT shortridgedee surveillanceofomadacyclineactivitytestedagainstclinicalisolatesfromtheunitedstatesandeuropeaspartofthe2016sentryantimicrobialsurveillanceprogram
AT flammrobertk surveillanceofomadacyclineactivitytestedagainstclinicalisolatesfromtheunitedstatesandeuropeaspartofthe2016sentryantimicrobialsurveillanceprogram

Ejemplares similares